<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: Free fatty acids act as signalling molecules for modulating insulin secretion, and their insulinotropic effects are <z:chebi fb="105" ids="17234">glucose</z:chebi>-dependent and mediated through G protein-coupled receptor 40 (GPR40) </plain></SENT>
<SENT sid="1" pm="."><plain>This mechanism is a potential target for new treatments for managing <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, we present the first clinical data for TAK-875, a novel highly selective, orally bioavailable GPR40 <z:chebi fb="4" ids="48705">agonist</z:chebi>, in Japanese patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> insufficiently controlled by diet or exercise therapy </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: This was an exploratory phase II, multicentre, randomized, double-blind, parallel group study comparing the efficacy and tolerability of TAK-875 100 and 400 mg, and placebo, <z:hpo ids='HP_0000001'>all</z:hpo> administered once daily for 2 weeks </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: After 2 weeks of treatment, TAK-875 produced marked <z:chebi fb="105" ids="17234">glucose</z:chebi> lowering effects in a 75 g oral <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance test (OGTT) as evidenced by mean ± SE intergroup differences in plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> AUC(0-3 h) of -12.98 ± 1.48 (p &lt; 0.0001) and -8.12 ± 1.49 mmol·h/l (p &lt; 0.0001), for TAK-875 400 mg vs. placebo and TAK-875 100 mg vs. placebo, respectively, and 2 h plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> [-4.95 ± 0.71 (p &lt; 0.0001) and -3.21 ± 0.71 mmol/l (p &lt; 0.0001), respectively] </plain></SENT>
<SENT sid="5" pm="."><plain>This was accompanied by a significant increase in insulin AUC(0-3 h) [34.68 ± 12.16 (p &lt; 0.01) and 31.49 ± 12.20 (p &lt; 0 · 05) µIU·h/ml, respectively] </plain></SENT>
<SENT sid="6" pm="."><plain>Improvement in glycaemic profile was mirrored by a significant change in fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> [-2.37 ± 0·27 (p &lt; 0.0001) and -1.88 ± 0.27 mmol/l (p &lt; 0.0001), respectively] </plain></SENT>
<SENT sid="7" pm="."><plain>No cases of <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> were observed despite the significant reduction in plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: These exploratory findings provide evidence of the <z:chebi fb="105" ids="17234">glucose</z:chebi>-dependent insulinotropic potential of the GPR40 <z:chebi fb="4" ids="48705">agonist</z:chebi> TAK-875, and the promising clinical changes support future longer term clinical investigation </plain></SENT>
</text></document>